{"id":1646,"date":"2007-05-31T12:12:30","date_gmt":"2007-05-31T11:12:30","guid":{"rendered":"http:\/\/www.ethicalquote.com\/index.php\/2007\/05\/31\/gsk-bms-jj-top-ethical-ranking-list-by-covalence\/"},"modified":"2007-06-11T09:16:36","modified_gmt":"2007-06-11T08:16:36","slug":"gsk-bms-jj-top-ethical-ranking-list-by-covalence","status":"publish","type":"post","link":"https:\/\/www.covalence.ch\/index.php\/2007\/05\/31\/gsk-bms-jj-top-ethical-ranking-list-by-covalence\/","title":{"rendered":"GSK, BMS, J&#038;J top ethical ranking list by Covalence"},"content":{"rendered":"<p><font size=\"2\"> GlaxoSmithKline is at the top of ethical-monitoring firm Covalence&#8217;s ranking list, followed by Bristol-Myers Squibb and Johnson &#038; Johnson. The quarterly report, which ranks the top 10 highest-ranking pharmas, reveals that the amount of revenue a company earns does not necessarily correspond to its ethical reputation. Pfizer, the world&#8217;s highest revenue-generating drug company, only placed fourth on the ethical table, whereas the next highest earner, Sanofi-Aventis barely made it into the ethical top 10, as did Merck &#038; Co, which is sixth-largest in terms of revenue. Fourth-largest revenue generator AstraZeneca and tenth revenue ranking Wyeth did not make the top 10 ethical list. GSK ranked third in earnings and first on the ethical list. Abbott Laboratories and Boehringer Ingelheim didn&#8217;t make the top 10 revenue list, but they did make the top 10 ethical list.<\/font><\/p>\n<p>Publication about Covalence <span class=\"LinkBlueTransMedium\">| Country: Global<\/span><span class=\"LinkBlueTransMedium\"><\/span><span class=\"LinkBlueTransMedium\"> | Company: <\/span><a href=\"http:\/\/www.ethicalquote.com\/newTemplate\/index.php\/ethicalquote\/?value=8\"><span style=\"font-size: 9pt; font-family: Arial\">GlaxoSmithKline, Bristol-Myers Squibb, Johnson &#038; Johnson, Pfizer, Abbott, Boehringer-Ingelheim, Merck &#038; Co, AstraZeneca<\/span><\/a><span class=\"LinkBlueTransMedium\"> |<\/span><span class=\"LinkBlueTransMedium\"> <\/span><span class=\"LinkBlueTransMedium\"><span class=\"LinkBluePgtMedium\"><\/span><\/span><span class=\"LinkBlueTransMedium\"> <\/span><span class=\"LinkBlueTransMedium\"><\/span>Source: <a href=\"http:\/\/www.politics.co.uk\/press-releases\/xopinion-formers\/d\/dr-hadwen-trust-ethical-ranking-top-pharma-companies-slammed-ignoring-animal-testing-$474329.htm\" target=\"_blank\" class=\"LinkBluePgtMedium\"><span style=\"font-size: 9pt; font-family: Arial\"><\/span><\/a><a href=\"http:\/\/ignitehealth.blogspot.com\/2007\/05\/gsk-bms-j-top-ethical-ranking-list-by.html\" target=\"_blank\">IgniteBLOG<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline is at the top of ethical-monitoring firm Covalence&#8217;s ranking list, followed by Bristol-Myers Squibb and Johnson &#038; Johnson. The quarterly report, which ranks the top 10 highest-ranking pharmas, reveals that the amount of revenue a company earns does not necessarily correspond to its ethical reputation. Pfizer, the world&#8217;s highest revenue-generating drug company, only placed&hellip;<\/p>\n","protected":false},"author":665,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"wds_primary_category":0,"wds_primary_post_series":0,"footnotes":""},"categories":[2],"tags":[104,102,105,101,62,30,40,42],"post_series":[],"class_list":["post-1646","post","type-post","status-publish","format-standard","hentry","category-publications","tag-abbott","tag-astrazeneca","tag-boehringer-ingelheim","tag-bristol-myers-squibb","tag-gsk","tag-jj","tag-merck-co","tag-pfizer","entry","no-media"],"_links":{"self":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/1646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/users\/665"}],"replies":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/comments?post=1646"}],"version-history":[{"count":0,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/1646\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/media?parent=1646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/categories?post=1646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/tags?post=1646"},{"taxonomy":"post_series","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/post_series?post=1646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}